You are here: Industry Insights > NMIBC

News List

LINDIS Biotech Reports Successful Initiation of Clinical Phase I Dose Escalation Study with the Trifunctional Antibody CATUMAXOMAB for Treatment of Non-Muscle-Invasive Bladder Cancer americanpharmaceuticalreview
April 14, 2021
LINDIS Biotech GmbH, a biopharmaceutical company with a proprietary multi-specific antibody platform and an advanced development pipeline with three clinical product candidates in immuno-oncology, announced the successful initiation of its clinical ...
LIPAC Oncology Announces Completion of LiPax Trial for Bladder Cancer americanpharmaceuticalreview
September 24, 2020
LIPAC Oncology announced the successful completion of a Phase 2A marker lesion clinical trial designed to predict long-term (two-year) recurrence free survival rates in patients with low-grade highly recurrent Non-Muscle Invasive Bladder Cancer (NMIBC)...
GeneCentric Therapeutics signs research alliance with Janssen pharmaceutical-technology
August 14, 2020
GeneCentric Therapeutics and Janssen Research & Development have formed a research alliance focused on RNA-based drug response biomarkers for non-muscle invasive bladder cancer (NMIBC).
FerGene’s phase 3 NMIBC study of Nadofaragene Firadenovec meets primary endpoint pharmaceutical-business-review
December 11, 2019
FerGene, a new gene therapy company formed by Ferring Pharmaceuticals and Blackstone Life Sciences, announced positive results from the pivotal Phase 3 clinical trial ...